Sentiment Summary
Recent Events
Q1 2026 earnings release scheduled.
Decided to cancel 9.11 million treasury shares (approx. 4% of total outstanding shares) worth about KRW 1.7154 trillion for shareholder value enhancement, as resolved at the annual general meeting on March 24, 2026. High impact is estimated due to the significant scale of the cancellation. The cancellation on April 1, 2026 is scheduled.
The 41st Annual General Meeting of Shareholders is scheduled for March 31, 2026. Agenda items include the approval of the 2025 financial statements and the appointment of new directors. scheduled
20th Annual General Meeting of Shareholders scheduled. Agenda includes approval of 2025 financial statements, appointment of a new internal director, and approval of director compensation limits. A low price impact is estimated as the agenda consists of routine administrative items scheduled.
Alteogen announced an exclusive license agreement with Biogen for its ALT-B4 technology worth up to $579 million on 2026-03-25. A high price impact (>10%) is estimated due to the substantial contract value and strategic partnership.
Entered into a license-in agreement with GoBioLab for three microbiome-based drug candidates for intestinal diseases. The deal is worth up to KRW 205.2 billion, including an upfront payment of KRW 1 billion.
Announced a 2026 operating profit target of KRW 1.8 trillion at its annual general meeting, with sequential quarterly growth from KRW 300 billion in Q1 to KRW 600 billion in Q4 expected.
Full-year 2025 earnings released. The company reported a significant increase in R&D expenses to 217.1 billion KRW, leading to an operating loss of 106.5 billion KRW despite revenue growth from technology transfers. A medium price impact is estimated due to the scale of the operating loss expected.